Warenkorb
Kostenloser Versand
Unsere Operationen sind klimaneutral

Modern Strategy for Preclinical Pharmaceutical R&D David Cavalla (Napp Research Centre, Cambridge, UK)

Modern Strategy for Preclinical Pharmaceutical R&D von David Cavalla (Napp Research Centre, Cambridge, UK)

Modern Strategy for Preclinical Pharmaceutical R&D David Cavalla (Napp Research Centre, Cambridge, UK)


€8.69
Zustand - Sehr Gut
Nur noch 1

Zusammenfassung

The emphasis on cost-effectiveness within the pharmaceutical industry has caused it to outsource some development work. This text addresses the advantages and disadvantages of collaborations between industrial research and development divisions and contract research organizations and universities.

Modern Strategy for Preclinical Pharmaceutical R&D Zusammenfassung

Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company David Cavalla (Napp Research Centre, Cambridge, UK)

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small biotechnology companies and research boutiques, and possibly even the virtual research company might play as contractors and collaborators.

Über David Cavalla (Napp Research Centre, Cambridge, UK)

David Cavalla is an expert on secondary uses for existing drugs, or drug repurposing. He currrently operates through his consultancy, Numedicus Ltd, having worked in drug repurposing for 15 years. Previously he was CEO of Arachnova, and prior to that held various senior positions in pharmaceutical drug discovery at GSK and Napp Research Centre. He has written widely on drug discovery strategy, and is the author of 70 published papers and patents.

Inhaltsverzeichnis

The Pharmaceutical Development Process.

The Advantages of Contracts and Collaborations.

The Disadvantages of Contracts and Collaborations.

The Role of Academic Institutes.

The Role of CROs and Small Research Companies.

Towards the Virtual Research Company.

References.

Index.

Zusätzliche Informationen

GOR010046643
9780471971177
0471971170
Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company David Cavalla (Napp Research Centre, Cambridge, UK)
Gebraucht - Sehr Gut
Gebundene Ausgabe
John Wiley & Sons Inc
19970321
228
N/A
Die Abbildung des Buches dient nur Illustrationszwecken, die tatsächliche Bindung, das Cover und die Auflage können sich davon unterscheiden.
Dies ist ein gebrauchtes Buch. Es wurde schon einmal gelesen und weist von der früheren Nutzung Gebrauchsspuren auf. Wir gehen davon aus, dass es im Großen und Ganzen in einem sehr guten Zustand ist. Sollten Sie jedoch nicht vollständig zufrieden sein, setzen Sie sich bitte mit uns in Verbindung.